	US 12,479,917 B2
	Methods of treating NSCLC comprising administering platinum doublet chemotherapy followed by an anti-PD-1 antibody and an anti-CTLA-4 antibody
Sabine Maier, Lawrenceville, NJ (US); Abderrahim Oukessou, Skillman, NJ (US); Nicholas Allan Botwood, Princeton, NJ (US); Kelly L. Covello, Philadelphia, PA (US); Michael V. Mandola, Williamstown, NJ (US); and Stephen R. Lane, Doylestown, PA (US)
Assigned to Bristol-Myers Squibb Company, Princeton, NJ (US)
Appl. No. 17/287,838
Filed by Bristol-Myers Squibb Company, Princeton, NJ (US)
PCT Filed Oct. 23, 2019, PCT No. PCT/US2019/057672 § 371(c)(1), (2) Date Apr. 22, 2021, PCT Pub. No. WO2020/086724, PCT Pub. Date Apr. 30, 2020.
Claims priority of provisional application 62/749,393, filed on Oct. 23, 2018.
Prior Publication US 2021/0380693 A1, Dec. 9, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 31/337 (2006.01); A61K 31/519 (2006.01); A61K 31/555 (2006.01); A61K 33/243 (2019.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)

CPC C07K 16/2818 (2013.01) [A61K 31/337 (2013.01); A61K 31/519 (2013.01); A61K 31/555 (2013.01); A61K 33/243 (2019.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 16/2827 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01)]

20 Claims

1. A method of treating a tumor in a subject afflicted with a non-small cell lung carcinoma (NSCLC), comprising:

(1) administering to the subject (i) a platinum doublet chemotherapy comprising carboplatin and paclitaxel, (ii) a flat dose of about 360 mg of an anti-PD-1 antibody or antigen binding portion thereof, and (iii) a dose of about 1 mg/kg of an anti-CTLA-4 antibody or antigen binding portion thereof on day 1 of a first 3-week cycle, and administering to the subject (i) the platinum based doublet chemotherapy and (ii) a flat dose of about 360 mg of the anti-PD-1 antibody on day 1 of a second 3 week cycle; and

(2) administering to the subject (i) a flat dose of about 360 mg of the anti-PD-1 antibody once about every 3 weeks and (ii) a dose of about 1 mg/kg of the anti-CTLA-4 antibody once about every 6 weeks.